Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management
Background and Aims Tolerance is transplantation’s holy grail, as it denotes allograft health without immunosuppression and its toxicities. Our aim was to determine, among stable long‐term pediatric liver transplant recipients, the efficacy and safety of immunosuppression withdrawal to identify oper...
Saved in:
Published in | Hepatology (Baltimore, Md.) Vol. 73; no. 5; pp. 1985 - 2004 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.05.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background and Aims
Tolerance is transplantation’s holy grail, as it denotes allograft health without immunosuppression and its toxicities. Our aim was to determine, among stable long‐term pediatric liver transplant recipients, the efficacy and safety of immunosuppression withdrawal to identify operational tolerance.
Approach and Results
We conducted a multicenter, single‐arm trial of immunosuppression withdrawal over 36‐48 weeks. Liver tests were monitored biweekly (year 1), monthly (year 2), and bimonthly (years 3‐4). For‐cause biopsies were done at investigators’ discretion but mandated when alanine aminotransferase or gamma glutamyltransferase exceeded 100 U/L. All subjects underwent final liver biopsy at trial end. The primary efficacy endpoint was operational tolerance, defined by strict biochemical and histological criteria 1 year after stopping immunosuppression. Among 88 subjects (median age 11 years; 39 boys; 57 deceased donor grafts), 33 (37.5%; 95% confidence interval [CI] 27.4%, 48.5%) were operationally tolerant, 16 were nontolerant by histology (met biochemical but failed histological criteria), and 39 were nontolerant by rejection. Rejection, predicted by subtle liver inflammation in trial entry biopsies, typically (n = 32) occurred at ≤32% of the trial‐entry immunosuppression dose and was treated with corticosteroids (n = 32) and/or tacrolimus (n = 38) with resolution (liver tests within 1.5 times the baseline) for all but 1 subject. No death, graft loss, or chronic, severe, or refractory rejection occurred. Neither fibrosis stage nor the expression level of a rejection gene set increased over 4 years for either tolerant or nontolerant subjects.
Conclusions
Immunosuppression withdrawal showed that 37.5% of selected pediatric liver‐transplant recipients were operationally tolerant. Allograft histology did not deteriorate for either tolerant or nontolerant subjects. The timing and reversibility of failed withdrawal justifies future trials exploring the efficacy, safety, and potential benefits of immunosuppression minimization. |
---|---|
AbstractList | BACKGROUND AND AIMSTolerance is transplantation's holy grail, as it denotes allograft health without immunosuppression and its toxicities. Our aim was to determine, among stable long-term pediatric liver transplant recipients, the efficacy and safety of immunosuppression withdrawal to identify operational tolerance.APPROACH AND RESULTSWe conducted a multicenter, single-arm trial of immunosuppression withdrawal over 36-48 weeks. Liver tests were monitored biweekly (year 1), monthly (year 2), and bimonthly (years 3-4). For-cause biopsies were done at investigators' discretion but mandated when alanine aminotransferase or gamma glutamyltransferase exceeded 100 U/L. All subjects underwent final liver biopsy at trial end. The primary efficacy endpoint was operational tolerance, defined by strict biochemical and histological criteria 1 year after stopping immunosuppression. Among 88 subjects (median age 11 years; 39 boys; 57 deceased donor grafts), 33 (37.5%; 95% confidence interval [CI] 27.4%, 48.5%) were operationally tolerant, 16 were nontolerant by histology (met biochemical but failed histological criteria), and 39 were nontolerant by rejection. Rejection, predicted by subtle liver inflammation in trial entry biopsies, typically (n = 32) occurred at ≤32% of the trial-entry immunosuppression dose and was treated with corticosteroids (n = 32) and/or tacrolimus (n = 38) with resolution (liver tests within 1.5 times the baseline) for all but 1 subject. No death, graft loss, or chronic, severe, or refractory rejection occurred. Neither fibrosis stage nor the expression level of a rejection gene set increased over 4 years for either tolerant or nontolerant subjects.CONCLUSIONSImmunosuppression withdrawal showed that 37.5% of selected pediatric liver-transplant recipients were operationally tolerant. Allograft histology did not deteriorate for either tolerant or nontolerant subjects. The timing and reversibility of failed withdrawal justifies future trials exploring the efficacy, safety, and potential benefits of immunosuppression minimization. Tolerance is transplantation's holy grail, as it denotes allograft health without immunosuppression and its toxicities. Our aim was to determine, among stable long-term pediatric liver transplant recipients, the efficacy and safety of immunosuppression withdrawal to identify operational tolerance. We conducted a multicenter, single-arm trial of immunosuppression withdrawal over 36-48 weeks. Liver tests were monitored biweekly (year 1), monthly (year 2), and bimonthly (years 3-4). For-cause biopsies were done at investigators' discretion but mandated when alanine aminotransferase or gamma glutamyltransferase exceeded 100 U/L. All subjects underwent final liver biopsy at trial end. The primary efficacy endpoint was operational tolerance, defined by strict biochemical and histological criteria 1 year after stopping immunosuppression. Among 88 subjects (median age 11 years; 39 boys; 57 deceased donor grafts), 33 (37.5%; 95% confidence interval [CI] 27.4%, 48.5%) were operationally tolerant, 16 were nontolerant by histology (met biochemical but failed histological criteria), and 39 were nontolerant by rejection. Rejection, predicted by subtle liver inflammation in trial entry biopsies, typically (n = 32) occurred at ≤32% of the trial-entry immunosuppression dose and was treated with corticosteroids (n = 32) and/or tacrolimus (n = 38) with resolution (liver tests within 1.5 times the baseline) for all but 1 subject. No death, graft loss, or chronic, severe, or refractory rejection occurred. Neither fibrosis stage nor the expression level of a rejection gene set increased over 4 years for either tolerant or nontolerant subjects. Immunosuppression withdrawal showed that 37.5% of selected pediatric liver-transplant recipients were operationally tolerant. Allograft histology did not deteriorate for either tolerant or nontolerant subjects. The timing and reversibility of failed withdrawal justifies future trials exploring the efficacy, safety, and potential benefits of immunosuppression minimization. Background and Aims Tolerance is transplantation’s holy grail, as it denotes allograft health without immunosuppression and its toxicities. Our aim was to determine, among stable long‐term pediatric liver transplant recipients, the efficacy and safety of immunosuppression withdrawal to identify operational tolerance. Approach and Results We conducted a multicenter, single‐arm trial of immunosuppression withdrawal over 36‐48 weeks. Liver tests were monitored biweekly (year 1), monthly (year 2), and bimonthly (years 3‐4). For‐cause biopsies were done at investigators’ discretion but mandated when alanine aminotransferase or gamma glutamyltransferase exceeded 100 U/L. All subjects underwent final liver biopsy at trial end. The primary efficacy endpoint was operational tolerance, defined by strict biochemical and histological criteria 1 year after stopping immunosuppression. Among 88 subjects (median age 11 years; 39 boys; 57 deceased donor grafts), 33 (37.5%; 95% confidence interval [CI] 27.4%, 48.5%) were operationally tolerant, 16 were nontolerant by histology (met biochemical but failed histological criteria), and 39 were nontolerant by rejection. Rejection, predicted by subtle liver inflammation in trial entry biopsies, typically (n = 32) occurred at ≤32% of the trial‐entry immunosuppression dose and was treated with corticosteroids (n = 32) and/or tacrolimus (n = 38) with resolution (liver tests within 1.5 times the baseline) for all but 1 subject. No death, graft loss, or chronic, severe, or refractory rejection occurred. Neither fibrosis stage nor the expression level of a rejection gene set increased over 4 years for either tolerant or nontolerant subjects. Conclusions Immunosuppression withdrawal showed that 37.5% of selected pediatric liver‐transplant recipients were operationally tolerant. Allograft histology did not deteriorate for either tolerant or nontolerant subjects. The timing and reversibility of failed withdrawal justifies future trials exploring the efficacy, safety, and potential benefits of immunosuppression minimization. |
Author | Lobritto, Steven J. Ng, Vicky L. Perito, Emily Demetris, Anthony J. Alonso, Estella M. Sundaram, Shikha S. Bridges, Nancy D. Kanaparthi, Sai Himes, Ryan W. Jose Lozano, Juan Gupta, Nitika A. Lesniak, Andrew Rand, Elizabeth B. Sherker, Averell H. Sanchez‐Fueyo, Alberto Venkat, Veena L. Martinez, Mercedes Feng, Sandy Doo, Edward Spain, Katharine M. Bucuvalas, John C. Magee, John C. Burrell, Bryna E. Turmelle, Yumirle P. Mazariegos, George V. Jackson, Annette M. Ikle, David Wood‐Trageser, Michele |
Author_xml | – sequence: 1 givenname: Sandy orcidid: 0000-0002-2601-4350 surname: Feng fullname: Feng, Sandy email: sandy.feng@ucsf.edu organization: University of California San Francisco – sequence: 2 givenname: John C. orcidid: 0000-0002-6767-8874 surname: Bucuvalas fullname: Bucuvalas, John C. organization: Mount Sinai Health System – sequence: 3 givenname: George V. orcidid: 0000-0002-2624-8632 surname: Mazariegos fullname: Mazariegos, George V. organization: Children’s Hospital of Pittsburgh – sequence: 4 givenname: John C. orcidid: 0000-0001-8416-7905 surname: Magee fullname: Magee, John C. organization: University of Michigan – sequence: 5 givenname: Alberto orcidid: 0000-0002-8316-3504 surname: Sanchez‐Fueyo fullname: Sanchez‐Fueyo, Alberto organization: King’s College London – sequence: 6 givenname: Katharine M. surname: Spain fullname: Spain, Katharine M. organization: Rho, Inc – sequence: 7 givenname: Andrew surname: Lesniak fullname: Lesniak, Andrew organization: University of Pittsburgh – sequence: 8 givenname: Sai surname: Kanaparthi fullname: Kanaparthi, Sai organization: The Immune Tolerance Network – sequence: 9 givenname: Emily orcidid: 0000-0002-2911-9684 surname: Perito fullname: Perito, Emily organization: University of California San Francisco – sequence: 10 givenname: Veena L. surname: Venkat fullname: Venkat, Veena L. organization: Children’s Hospital of Pittsburgh – sequence: 11 givenname: Bryna E. surname: Burrell fullname: Burrell, Bryna E. organization: The Immune Tolerance Network – sequence: 12 givenname: Estella M. surname: Alonso fullname: Alonso, Estella M. organization: Ann & Robert H. Lurie Children’s Hospital of Chicago – sequence: 13 givenname: Nancy D. orcidid: 0000-0002-1140-5201 surname: Bridges fullname: Bridges, Nancy D. organization: National Institute of Allergy and Infectious Diseases – sequence: 14 givenname: Edward surname: Doo fullname: Doo, Edward organization: National Institute of Diabetes and Digestive and Kidney Diseases – sequence: 15 givenname: Nitika A. orcidid: 0000-0002-6171-4731 surname: Gupta fullname: Gupta, Nitika A. organization: Emory University School of Medicine – sequence: 16 givenname: Ryan W. orcidid: 0000-0002-0116-2613 surname: Himes fullname: Himes, Ryan W. organization: Texas Children’s Hospital – sequence: 17 givenname: David orcidid: 0000-0003-0091-5246 surname: Ikle fullname: Ikle, David organization: Rho, Inc – sequence: 18 givenname: Annette M. surname: Jackson fullname: Jackson, Annette M. organization: Duke University – sequence: 19 givenname: Steven J. surname: Lobritto fullname: Lobritto, Steven J. organization: Columbia University Irving Medical Center – sequence: 20 givenname: Juan orcidid: 0000-0001-7613-3908 surname: Jose Lozano fullname: Jose Lozano, Juan organization: Instituto de Salud Carlos III – sequence: 21 givenname: Mercedes orcidid: 0000-0001-6128-0155 surname: Martinez fullname: Martinez, Mercedes organization: Columbia University Irving Medical Center – sequence: 22 givenname: Vicky L. orcidid: 0000-0002-9998-5692 surname: Ng fullname: Ng, Vicky L. organization: University of Toronto – sequence: 23 givenname: Elizabeth B. orcidid: 0000-0002-1173-4558 surname: Rand fullname: Rand, Elizabeth B. organization: The Children’s Hospital of Pennsylvania – sequence: 24 givenname: Averell H. orcidid: 0000-0003-0409-6938 surname: Sherker fullname: Sherker, Averell H. organization: National Institute of Diabetes and Digestive and Kidney Diseases – sequence: 25 givenname: Shikha S. surname: Sundaram fullname: Sundaram, Shikha S. organization: University of Colorado School of Medicine – sequence: 26 givenname: Yumirle P. surname: Turmelle fullname: Turmelle, Yumirle P. organization: Washington University School of Medicine – sequence: 27 givenname: Michele orcidid: 0000-0002-1880-4926 surname: Wood‐Trageser fullname: Wood‐Trageser, Michele organization: University of Pittsburgh – sequence: 28 givenname: Anthony J. surname: Demetris fullname: Demetris, Anthony J. organization: University of Pittsburgh |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32786149$$D View this record in MEDLINE/PubMed |
BookMark | eNp10UFv1DAQBWALFdFt4cAfQJa4wCHt2E7iDTdULW2lrahgEcdoEk9aV4kd7KSr5do_jssWDkic5vLN05PeETtw3hFjrwWcCAB5ekvjiRKFhGdskY7OlCrggC1AasgqoapDdhTjHQBUuVy-YIdK6mUp8mrBHlZdZ1tsdxyd4V-xo2nHfccvh2F2Ps7jGChG6x3_bqdbE3CLPbeOX5OxOAXb8rW9p8A3AV0ce3QT_0KtHS25KX7gV_7euhu-8VsMJj2F6B329icZfoUOb2hI7iV73mEf6dXTPWbfPq02ZxfZ-vP55dnHddbmRQ6ZLJUBiY0plmXVFBoBhG5KzEmWAI1uATutNJbUoVHULjVqKXJhzLITVanUMXu3zx2D_zFTnOrBxpb61Jr8HGuZqxyKqtQy0bf_0Ds_h1Q9qUJUKuXJR_V-r9rgYwzU1WOwA4ZdLaB-XKZOy9S_l0n2zVPi3Axk_so_UyRwugdb29Pu_0n1xep6H_kLL9Oapg |
CitedBy_id | crossref_primary_10_1111_petr_14251 crossref_primary_10_1016_j_trim_2023_101827 crossref_primary_10_1172_jci_insight_159205 crossref_primary_10_3390_ijms22052253 crossref_primary_10_1016_j_eclinm_2022_101752 crossref_primary_10_1111_petr_14575 crossref_primary_10_3390_transplantology2040042 crossref_primary_10_1016_j_jhep_2023_01_030 crossref_primary_10_1038_s41591_022_01758_7 crossref_primary_10_1097_TP_0000000000004160 crossref_primary_10_1002_lt_26479 crossref_primary_10_1186_s12893_021_01402_0 crossref_primary_10_1111_ctr_15085 crossref_primary_10_1016_j_aohep_2022_100760 crossref_primary_10_1002_lt_26270 crossref_primary_10_1111_ajt_16585 crossref_primary_10_3389_fped_2023_1172516 crossref_primary_10_1002_lt_26474 crossref_primary_10_1111_liv_15764 crossref_primary_10_1016_j_jhep_2024_05_032 crossref_primary_10_3390_cells11010024 crossref_primary_10_1002_lt_26502 crossref_primary_10_1016_j_bpg_2021_101770 crossref_primary_10_32074_1591_951X_753 crossref_primary_10_1097_LVT_0000000000000300 crossref_primary_10_1097_TP_0000000000003896 crossref_primary_10_1016_j_ajt_2024_01_030 crossref_primary_10_1016_j_ajt_2023_04_003 crossref_primary_10_1002_lt_26420 crossref_primary_10_1002_jhbp_1077 crossref_primary_10_1097_TP_0000000000004580 crossref_primary_10_1097_TP_0000000000004183 crossref_primary_10_1097_TP_0000000000003650 crossref_primary_10_1111_ctr_14894 crossref_primary_10_1016_j_jhep_2021_07_027 crossref_primary_10_3389_frtra_2023_1168163 crossref_primary_10_3389_fimmu_2021_719954 crossref_primary_10_1007_s00281_022_00958_0 crossref_primary_10_1097_LVT_0000000000000334 crossref_primary_10_1097_LVT_0000000000000330 crossref_primary_10_1016_j_suc_2022_07_006 crossref_primary_10_1097_TP_0000000000004557 crossref_primary_10_1016_j_jhep_2021_08_007 crossref_primary_10_1097_TP_0000000000004637 crossref_primary_10_3748_wjg_v30_i13_1791 crossref_primary_10_3390_jcm10225417 crossref_primary_10_1016_j_transproceed_2021_08_065 crossref_primary_10_1177_09636897241256462 crossref_primary_10_1016_j_transproceed_2022_04_023 crossref_primary_10_1097_TP_0000000000004473 crossref_primary_10_1016_j_ajt_2024_03_008 crossref_primary_10_1016_j_scib_2022_09_017 crossref_primary_10_1016_j_jpeds_2023_113744 crossref_primary_10_1111_petr_14569 crossref_primary_10_1002_hep_32666 crossref_primary_10_1016_j_jceh_2022_09_002 crossref_primary_10_1002_lt_26409 |
Cites_doi | 10.1016/j.healun.2016.05.020 10.1111/j.1600-6143.2012.04210.x 10.1002/lt.24845 10.1002/lt.25411 10.1097/TP.0b013e31818febc4 10.1002/hep.22686 10.1111/ajt.12667 10.1002/hep.510280223 10.1016/j.jhep.2015.05.033 10.1053/j.gastro.2018.08.023 10.1002/lt.25305 10.1111/j.1600-6143.2007.01893.x 10.1016/j.humimm.2016.02.006 10.1111/ajt.13909 10.1111/ajt.13488 10.1002/hep.28459 10.1111/ajt.15205 10.1002/hep.27254 10.1002/hep.30281 10.1542/peds.2013-0904 10.1111/j.1600-6143.2012.03995.x 10.1002/hep.26426 10.1111/j.1600-6143.2007.01923.x 10.1002/lt.25177 10.1097/TP.0b013e3182845f6c 10.1172/JCI59411 10.1002/lt.23481 10.1002/hep.21152 10.1002/hep.28681 10.1016/j.humimm.2017.10.007 10.1097/TP.0000000000000796 10.1002/lt.25431 10.1681/ASN.2014121234 10.1016/j.cgh.2016.07.035 10.1002/hep.27793 10.1002/lt.23534 10.1111/j.1399-0012.2007.00788.x 10.1111/ajt.13347 10.1111/ajt.15621 10.1002/lt.21444 10.1111/ajt.13617 10.1097/TP.0b013e318244f7b8 10.1016/j.jpeds.2011.10.038 10.1016/j.jhep.2018.04.012 10.1111/ajt.14626 10.1002/lt.21549 |
ContentType | Journal Article |
Copyright | 2020 by the American Association for the Study of Liver Diseases. 2021 by the American Association for the Study of Liver Diseases. |
Copyright_xml | – notice: 2020 by the American Association for the Study of Liver Diseases. – notice: 2021 by the American Association for the Study of Liver Diseases. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
DOI | 10.1002/hep.31520 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1527-3350 |
EndPage | 2004 |
ExternalDocumentID | 10_1002_hep_31520 32786149 HEP31520 |
Genre | article Multicenter Study Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: National Institute of Diabetes and Digestive and Kidney Diseases funderid: U01‐AI‐100807 – fundername: National Institute of Allergy and Infectious Diseases funderid: U01‐AI‐100807 – fundername: Immune Tolerance Network funderid: UM1AI109565 – fundername: NCATS NIH HHS grantid: UL1 TR001878 – fundername: NCATS NIH HHS grantid: UL1 TR000004 – fundername: NCATS NIH HHS grantid: UL1 TR000454 – fundername: NIAID NIH HHS grantid: U01 AI100807 – fundername: Medical Research Council grantid: MC_PC_15108 – fundername: NCATS NIH HHS grantid: UL1 TR000003 – fundername: NCATS NIH HHS grantid: UL1 TR001425 – fundername: NCATS NIH HHS grantid: UL1 TR002378 |
GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX ACLDA ACRPL ACYXJ ADNMO CITATION 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
ID | FETCH-LOGICAL-c4540-263d02abd5869b57a0017b6a4e2600b7c0af737a6efad3ec87a72141dd8f19633 |
IEDL.DBID | DR2 |
ISSN | 0270-9139 |
IngestDate | Tue Dec 03 23:38:39 EST 2024 Thu Oct 10 18:07:03 EDT 2024 Fri Dec 06 07:53:00 EST 2024 Sat Nov 02 11:56:47 EDT 2024 Sat Aug 24 01:03:44 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
License | 2020 by the American Association for the Study of Liver Diseases. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4540-263d02abd5869b57a0017b6a4e2600b7c0af737a6efad3ec87a72141dd8f19633 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-1880-4926 0000-0003-0409-6938 0000-0001-7613-3908 0000-0003-0091-5246 0000-0002-2601-4350 0000-0002-1140-5201 0000-0002-0116-2613 0000-0002-8316-3504 0000-0002-6171-4731 0000-0001-6128-0155 0000-0002-9998-5692 0000-0002-2911-9684 0000-0002-1173-4558 0000-0001-8416-7905 0000-0002-2624-8632 0000-0002-6767-8874 |
OpenAccessLink | http://deepblue.lib.umich.edu/bitstream/2027.42/167499/2/hep31520.pdf |
PMID | 32786149 |
PQID | 2519319622 |
PQPubID | 996352 |
PageCount | 20 |
ParticipantIDs | proquest_miscellaneous_2434059672 proquest_journals_2519319622 crossref_primary_10_1002_hep_31520 pubmed_primary_32786149 wiley_primary_10_1002_hep_31520_HEP31520 |
PublicationCentury | 2000 |
PublicationDate | May 2021 |
PublicationDateYYYYMMDD | 2021-05-01 |
PublicationDate_xml | – month: 05 year: 2021 text: May 2021 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Hepatology (Baltimore, Md.) |
PublicationTitleAlternate | Hepatology |
PublicationYear | 2021 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2015; 15 1998; 28 2012; 122 2020; 20 2017; 65 2015; 99 2017; 23 2012; 160 2008; 14 2019; 19 2012; 18 2018; 22 2016; 16 2012; 12 2014; 60 2009; 49 2016; 35 2012; 307 2018; 69 2018; 24 2016; 77 2012; 93 2018; 155 2018; 18 2015; 26 2013; 58 2017; 15 2006; 43 2015; 62 2013; 95 2015; 63 2019; 25 2019; 69 2016; 64 2019 2014; 14 2007; 7 2008; 22 2013; 132 2008; 86 2018; 79 (hep31520-bib-0002-20241017) 2006; 43 (hep31520-bib-0021-20241017) 2019; 19 (hep31520-bib-0041-20241017) 2016; 64 (hep31520-bib-0029-20241017) 2018; 69 (hep31520-bib-0033-20241017) 2015; 15 (hep31520-bib-0007-20241017) 2009; 49 (hep31520-bib-0004-20241017) 2018; 22 (hep31520-bib-0014-20241017) 2018; 79 (hep31520-bib-0016-20241017) 2013; 95 (hep31520-bib-0022-20241017) 2012; 18 (hep31520-bib-0045-20241017) 1998; 28 (hep31520-bib-0012-20241017) 2013; 132 (hep31520-bib-0047-20241017) 2015; 63 (hep31520-bib-0037-20241017) 2014; 14 (hep31520-bib-0008-20241017) 2015; 99 (hep31520-bib-0020-20241017) 2012; 307 (hep31520-bib-0042-20241017) 2014; 60 (hep31520-bib-0023-20241017) 2016; 16 (hep31520-bib-0049-20241017) 2016; 16 (hep31520-bib-0010-20241017) 2018; 18 (hep31520-bib-0018-20241017) 2019; 25 (hep31520-bib-0001-20241017) 2008; 14 (hep31520-bib-0024-20241017) 2012; 122 (hep31520-bib-0028-20241017) 2007; 7 (hep31520-bib-0005-20241017) 2008; 14 (hep31520-bib-0043-20241017) 2020; 20 (hep31520-bib-0035-20241017) 2016; 35 (hep31520-bib-0013-20241017) 2017; 23 (hep31520-bib-0038-20241017) 2017; 65 (hep31520-bib-0006-20241017) 2012; 18 (hep31520-bib-0030-20241017) 2007; 7 (hep31520-bib-0032-20241017) 2019; 69 (hep31520-bib-0044-20241017) 2019 (hep31520-bib-0003-20241017) 2018; 155 (hep31520-bib-0031-20241017) 2015; 26 (hep31520-bib-0015-20241017) 2008; 22 (hep31520-bib-0009-20241017) 2018; 24 (hep31520-bib-0040-20241017) 2018; 24 (hep31520-bib-0011-20241017) 2019; 25 (hep31520-bib-0026-20241017) 2016; 16 (hep31520-bib-0025-20241017) 2012; 12 (hep31520-bib-0046-20241017) 2015; 62 (hep31520-bib-0019-20241017) 2013; 58 (hep31520-bib-0017-20241017) 2017; 15 (hep31520-bib-0039-20241017) 2016; 77 (hep31520-bib-0034-20241017) 2012; 93 (hep31520-bib-0027-20241017) 2012; 160 (hep31520-bib-0048-20241017) 2008; 86 (hep31520-bib-0036-20241017) 2012; 12 |
References_xml | – volume: 69 start-page: 1273 year: 2019 end-page: 1286 article-title: Prevalence and impact of de novo donor‐specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients publication-title: Hepatology – volume: 86 start-page: 1837 year: 2008 end-page: 1843 article-title: The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients publication-title: Transplantation – volume: 69 start-page: 626 year: 2018 end-page: 634 article-title: Molecular profiling of subclinical inflammatory lesions in long‐term surviving adult liver transplant recipients publication-title: J Hepatol – volume: 18 start-page: 1680 year: 2018 end-page: 1689 article-title: Long‐term outcome of liver transplantation in childhood: a study of 20‐year survivors publication-title: Am J Transplant – volume: 15 start-page: 584 year: 2017 end-page: 593.e582 article-title: Acute rejection increases risk of graft failure and death in recent liver transplant recipients publication-title: Clin Gastroenterol Hepatol – volume: 25 start-page: 425 year: 2019 end-page: 435 article-title: Not all cellular rejections are the same: differences in early and late hepatic allograft rejection publication-title: Liver Transpl – volume: 95 start-page: 955 year: 2013 end-page: 959 article-title: Late acute liver allograft rejection; a study of its natural history and graft survival in the current era publication-title: Transplantation – volume: 122 start-page: 368 year: 2012 end-page: 382 article-title: Intra‐graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation publication-title: J Clin Invest – volume: 20 start-page: 513 year: 2020 end-page: 524 article-title: IgG4 donor‐specific HLA antibody profile is associated with subclinical rejection in stable pediatric liver recipients publication-title: Am J Transplant – volume: 7 start-page: 2165 year: 2007 end-page: 2171 article-title: Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database publication-title: Am J Transplant – volume: 22 start-page: 316 year: 2008 end-page: 323 article-title: Late acute rejection after liver transplantation impacts patient survival publication-title: Clin Transplant – volume: 16 start-page: 484 year: 2016 end-page: 496 article-title: Molecular characterization of acute cellular rejection occurring during intentional immunosuppression withdrawal in liver transplantation publication-title: Am J Transplant – volume: 14 start-page: 1582 year: 2008 end-page: 1587 article-title: Graft histology characteristics in long‐term survivors of pediatric liver transplantation publication-title: Liver Transpl – volume: 49 start-page: 880 year: 2009 end-page: 886 article-title: Graft fibrosis after pediatric liver transplantation: ten years of follow‐up publication-title: Hepatology – year: 2019 article-title: Immunosuppression withdrawal in liver transplant recipients on sirolimus publication-title: Hepatology – volume: 24 start-page: 1091 year: 2018 end-page: 1100 article-title: Prevalence, risk factors, and impact of donor‐specific alloantibodies after adult liver transplantation publication-title: Liver Transpl – volume: 160 start-page: 820 year: 2012 end-page: 826.e823 article-title: Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience publication-title: J Pediatr – volume: 43 start-page: 1109 year: 2006 end-page: 1117 article-title: Progressive histological damage in liver allografts following pediatric liver transplantation publication-title: Hepatology – volume: 14 start-page: 946 year: 2008 end-page: 955 article-title: Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients publication-title: Liver Transpl – volume: 22 year: 2018 article-title: Obliterative portal venopathy: a histopathologic finding associated with chronic antibody‐mediated rejection in pediatric liver allografts publication-title: Pediatr Transplant – volume: 18 start-page: 1333 year: 2012 end-page: 1342 article-title: Progressive graft fibrosis and donor‐specific human leukocyte antigen antibodies in pediatric late liver allografts publication-title: Liver Transpl – volume: 64 start-page: 632 year: 2016 end-page: 643 article-title: A pilot study of operational tolerance with a regulatory T cell‐based cell therapy in living donor liver transplantation publication-title: Hepatology – volume: 12 start-page: 1504 year: 2012 end-page: 1510 article-title: Prevalence, course and impact of HLA donor‐specific antibodies in liver transplantation in the first year publication-title: Am J Transplant – volume: 16 start-page: 1285 year: 2016 end-page: 1293 article-title: Hepatic infiltrates in operational tolerant patients after liver transplantation show enrichment of regulatory T cells before proinflammatory genes are downregulated publication-title: Am J Transplant – volume: 77 start-page: 1063 year: 2016 end-page: 1070 article-title: Donor‐specific antibodies and liver transplantation publication-title: Hum Immunol – volume: 23 start-page: 1601 year: 2017 end-page: 1614 article-title: Tolerance after liver transplantation: where are we? publication-title: Liver Transpl – volume: 93 start-page: 650 year: 2012 end-page: 656 article-title: Late antibody‐mediated rejection after heart transplantation following the development of de novo donor‐specific human leukocyte antigen antibody publication-title: Transplantation – volume: 24 start-page: 1252 year: 2018 end-page: 1259 article-title: Cancer after liver transplantation in children and young adults: a population‐based study from 4 nordic countries publication-title: Liver Transpl – volume: 7 start-page: 2311 year: 2007 end-page: 2317 article-title: High risk of sensitization after failed islet transplantation publication-title: Am J Transplant – volume: 16 start-page: 2816 year: 2016 end-page: 2835 article-title: 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody‐mediated rejection publication-title: Am J Transplant – volume: 62 start-page: 279 year: 2015 end-page: 291 article-title: Liver inflammation abrogates immunological tolerance induced by Kupffer cells publication-title: Hepatology – volume: 132 start-page: e1319 year: 2013 end-page: e1326 article-title: End‐stage kidney disease after pediatric nonrenal solid organ transplantation publication-title: Pediatrics – volume: 14 start-page: 779 year: 2014 end-page: 787 article-title: The role of donor‐specific HLA alloantibodies in liver transplantation publication-title: Am J Transplant – volume: 28 start-page: 443 year: 1998 end-page: 449 article-title: Tolerance and latent cellular rejection in long‐term liver transplant recipients publication-title: Hepatology – volume: 99 start-page: 1416 year: 2015 end-page: 1422 article-title: Donor‐specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation publication-title: Transplantation – volume: 58 start-page: 1824 year: 2013 end-page: 1835 article-title: Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients publication-title: Hepatology – volume: 18 start-page: 1154 year: 2012 end-page: 1170 article-title: Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance publication-title: Liver Transplant – volume: 155 start-page: 1838 year: 2018 end-page: 1851.e1837 article-title: Evidence of chronic allograft injury in liver biopsies from long‐term pediatric recipients of liver transplants publication-title: Gastroenterology – volume: 19 start-page: 1397 year: 2019 end-page: 1409 article-title: Outcomes of immunosuppression minimization and withdrawal early after liver transplantation publication-title: Am J Transplant – volume: 63 start-page: 1005 year: 2015 end-page: 1014 article-title: Immune outcomes in the liver: Is CD8 T cell fate determined by the environment? publication-title: J Hepatol – volume: 26 start-page: 3114 year: 2015 end-page: 3122 article-title: Adverse outcomes of tacrolimus withdrawal in immune‐quiescent kidney transplant recipients publication-title: J Am Soc Nephrol – volume: 12 start-page: 2986 year: 2012 end-page: 2996 article-title: Novel histologic scoring system for long‐term allograft fibrosis after liver transplantation in children publication-title: Am J Transplant – volume: 60 start-page: 2109 year: 2014 end-page: 2117 article-title: Immune tolerance in liver disease publication-title: Hepatology – volume: 79 start-page: 283 year: 2018 end-page: 287 article-title: Tolerance in clinical liver transplantation publication-title: Hum Immunol – volume: 307 start-page: 283 year: 2012 end-page: 293 article-title: Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants publication-title: JAMA – volume: 65 start-page: 647 year: 2017 end-page: 660 article-title: Five‐year histological and serological follow‐up of operationally tolerant pediatric liver transplant recipients enrolled in WISP‐R publication-title: Hepatology – volume: 35 start-page: 1067 year: 2016 end-page: 1077 article-title: De‐novo donor‐specific anti‐HLA antibodies 30 days after lung transplantation are associated with a worse outcome publication-title: J Heart Lung Transplant – volume: 25 start-page: 752 year: 2019 end-page: 762 article-title: High burden of subclinical cardiovascular target organ damage after pediatric liver transplantation publication-title: Liver Transpl – volume: 15 start-page: 2921 year: 2015 end-page: 2930 article-title: Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor‐specific antibody publication-title: Am J Transplant – volume: 35 start-page: 1067 year: 2016 ident: hep31520-bib-0035-20241017 article-title: De‐novo donor‐specific anti‐HLA antibodies 30 days after lung transplantation are associated with a worse outcome publication-title: J Heart Lung Transplant doi: 10.1016/j.healun.2016.05.020 – volume: 12 start-page: 2986 year: 2012 ident: hep31520-bib-0025-20241017 article-title: Novel histologic scoring system for long‐term allograft fibrosis after liver transplantation in children publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2012.04210.x – volume: 23 start-page: 1601 year: 2017 ident: hep31520-bib-0013-20241017 article-title: Tolerance after liver transplantation: where are we? publication-title: Liver Transpl doi: 10.1002/lt.24845 – volume: 25 start-page: 425 year: 2019 ident: hep31520-bib-0018-20241017 article-title: Not all cellular rejections are the same: differences in early and late hepatic allograft rejection publication-title: Liver Transpl doi: 10.1002/lt.25411 – volume: 86 start-page: 1837 year: 2008 ident: hep31520-bib-0048-20241017 article-title: The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients publication-title: Transplantation doi: 10.1097/TP.0b013e31818febc4 – volume: 49 start-page: 880 year: 2009 ident: hep31520-bib-0007-20241017 article-title: Graft fibrosis after pediatric liver transplantation: ten years of follow‐up publication-title: Hepatology doi: 10.1002/hep.22686 – volume: 14 start-page: 779 year: 2014 ident: hep31520-bib-0037-20241017 article-title: The role of donor‐specific HLA alloantibodies in liver transplantation publication-title: Am J Transplant doi: 10.1111/ajt.12667 – year: 2019 ident: hep31520-bib-0044-20241017 article-title: Immunosuppression withdrawal in liver transplant recipients on sirolimus publication-title: Hepatology – volume: 28 start-page: 443 year: 1998 ident: hep31520-bib-0045-20241017 article-title: Tolerance and latent cellular rejection in long‐term liver transplant recipients publication-title: Hepatology doi: 10.1002/hep.510280223 – volume: 63 start-page: 1005 year: 2015 ident: hep31520-bib-0047-20241017 article-title: Immune outcomes in the liver: Is CD8 T cell fate determined by the environment? publication-title: J Hepatol doi: 10.1016/j.jhep.2015.05.033 – volume: 155 start-page: 1838 year: 2018 ident: hep31520-bib-0003-20241017 article-title: Evidence of chronic allograft injury in liver biopsies from long‐term pediatric recipients of liver transplants publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.08.023 – volume: 24 start-page: 1252 year: 2018 ident: hep31520-bib-0009-20241017 article-title: Cancer after liver transplantation in children and young adults: a population‐based study from 4 nordic countries publication-title: Liver Transpl doi: 10.1002/lt.25305 – volume: 7 start-page: 2165 year: 2007 ident: hep31520-bib-0028-20241017 article-title: Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2007.01893.x – volume: 77 start-page: 1063 year: 2016 ident: hep31520-bib-0039-20241017 article-title: Donor‐specific antibodies and liver transplantation publication-title: Hum Immunol doi: 10.1016/j.humimm.2016.02.006 – volume: 16 start-page: 2816 year: 2016 ident: hep31520-bib-0026-20241017 article-title: 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody‐mediated rejection publication-title: Am J Transplant doi: 10.1111/ajt.13909 – volume: 16 start-page: 484 year: 2016 ident: hep31520-bib-0023-20241017 article-title: Molecular characterization of acute cellular rejection occurring during intentional immunosuppression withdrawal in liver transplantation publication-title: Am J Transplant doi: 10.1111/ajt.13488 – volume: 64 start-page: 632 year: 2016 ident: hep31520-bib-0041-20241017 article-title: A pilot study of operational tolerance with a regulatory T cell‐based cell therapy in living donor liver transplantation publication-title: Hepatology doi: 10.1002/hep.28459 – volume: 19 start-page: 1397 year: 2019 ident: hep31520-bib-0021-20241017 article-title: Outcomes of immunosuppression minimization and withdrawal early after liver transplantation publication-title: Am J Transplant doi: 10.1111/ajt.15205 – volume: 60 start-page: 2109 year: 2014 ident: hep31520-bib-0042-20241017 article-title: Immune tolerance in liver disease publication-title: Hepatology doi: 10.1002/hep.27254 – volume: 69 start-page: 1273 year: 2019 ident: hep31520-bib-0032-20241017 article-title: Prevalence and impact of de novo donor‐specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients publication-title: Hepatology doi: 10.1002/hep.30281 – volume: 132 start-page: e1319 year: 2013 ident: hep31520-bib-0012-20241017 article-title: End‐stage kidney disease after pediatric nonrenal solid organ transplantation publication-title: Pediatrics doi: 10.1542/peds.2013-0904 – volume: 12 start-page: 1504 year: 2012 ident: hep31520-bib-0036-20241017 article-title: Prevalence, course and impact of HLA donor‐specific antibodies in liver transplantation in the first year publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2012.03995.x – volume: 58 start-page: 1824 year: 2013 ident: hep31520-bib-0019-20241017 article-title: Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients publication-title: Hepatology doi: 10.1002/hep.26426 – volume: 7 start-page: 2311 year: 2007 ident: hep31520-bib-0030-20241017 article-title: High risk of sensitization after failed islet transplantation publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2007.01923.x – volume: 24 start-page: 1091 year: 2018 ident: hep31520-bib-0040-20241017 article-title: Prevalence, risk factors, and impact of donor‐specific alloantibodies after adult liver transplantation publication-title: Liver Transpl doi: 10.1002/lt.25177 – volume: 95 start-page: 955 year: 2013 ident: hep31520-bib-0016-20241017 article-title: Late acute liver allograft rejection; a study of its natural history and graft survival in the current era publication-title: Transplantation doi: 10.1097/TP.0b013e3182845f6c – volume: 122 start-page: 368 year: 2012 ident: hep31520-bib-0024-20241017 article-title: Intra‐graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation publication-title: J Clin Invest doi: 10.1172/JCI59411 – volume: 18 start-page: 1154 year: 2012 ident: hep31520-bib-0022-20241017 article-title: Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance publication-title: Liver Transplant doi: 10.1002/lt.23481 – volume: 43 start-page: 1109 year: 2006 ident: hep31520-bib-0002-20241017 article-title: Progressive histological damage in liver allografts following pediatric liver transplantation publication-title: Hepatology doi: 10.1002/hep.21152 – volume: 65 start-page: 647 year: 2017 ident: hep31520-bib-0038-20241017 article-title: Five‐year histological and serological follow‐up of operationally tolerant pediatric liver transplant recipients enrolled in WISP‐R publication-title: Hepatology doi: 10.1002/hep.28681 – volume: 79 start-page: 283 year: 2018 ident: hep31520-bib-0014-20241017 article-title: Tolerance in clinical liver transplantation publication-title: Hum Immunol doi: 10.1016/j.humimm.2017.10.007 – volume: 99 start-page: 1416 year: 2015 ident: hep31520-bib-0008-20241017 article-title: Donor‐specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation publication-title: Transplantation doi: 10.1097/TP.0000000000000796 – volume: 25 start-page: 752 year: 2019 ident: hep31520-bib-0011-20241017 article-title: High burden of subclinical cardiovascular target organ damage after pediatric liver transplantation publication-title: Liver Transpl doi: 10.1002/lt.25431 – volume: 26 start-page: 3114 year: 2015 ident: hep31520-bib-0031-20241017 article-title: Adverse outcomes of tacrolimus withdrawal in immune‐quiescent kidney transplant recipients publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2014121234 – volume: 22 year: 2018 ident: hep31520-bib-0004-20241017 article-title: Obliterative portal venopathy: a histopathologic finding associated with chronic antibody‐mediated rejection in pediatric liver allografts publication-title: Pediatr Transplant – volume: 15 start-page: 584 year: 2017 ident: hep31520-bib-0017-20241017 article-title: Acute rejection increases risk of graft failure and death in recent liver transplant recipients publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2016.07.035 – volume: 62 start-page: 279 year: 2015 ident: hep31520-bib-0046-20241017 article-title: Liver inflammation abrogates immunological tolerance induced by Kupffer cells publication-title: Hepatology doi: 10.1002/hep.27793 – volume: 18 start-page: 1333 year: 2012 ident: hep31520-bib-0006-20241017 article-title: Progressive graft fibrosis and donor‐specific human leukocyte antigen antibodies in pediatric late liver allografts publication-title: Liver Transpl doi: 10.1002/lt.23534 – volume: 22 start-page: 316 year: 2008 ident: hep31520-bib-0015-20241017 article-title: Late acute rejection after liver transplantation impacts patient survival publication-title: Clin Transplant doi: 10.1111/j.1399-0012.2007.00788.x – volume: 15 start-page: 2921 year: 2015 ident: hep31520-bib-0033-20241017 article-title: Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor‐specific antibody publication-title: Am J Transplant doi: 10.1111/ajt.13347 – volume: 20 start-page: 513 year: 2020 ident: hep31520-bib-0043-20241017 article-title: IgG4 donor‐specific HLA antibody profile is associated with subclinical rejection in stable pediatric liver recipients publication-title: Am J Transplant doi: 10.1111/ajt.15621 – volume: 14 start-page: 946 year: 2008 ident: hep31520-bib-0005-20241017 article-title: Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients publication-title: Liver Transpl doi: 10.1002/lt.21444 – volume: 16 start-page: 1285 year: 2016 ident: hep31520-bib-0049-20241017 article-title: Hepatic infiltrates in operational tolerant patients after liver transplantation show enrichment of regulatory T cells before proinflammatory genes are downregulated publication-title: Am J Transplant doi: 10.1111/ajt.13617 – volume: 93 start-page: 650 year: 2012 ident: hep31520-bib-0034-20241017 article-title: Late antibody‐mediated rejection after heart transplantation following the development of de novo donor‐specific human leukocyte antigen antibody publication-title: Transplantation doi: 10.1097/TP.0b013e318244f7b8 – volume: 307 start-page: 283 year: 2012 ident: hep31520-bib-0020-20241017 article-title: Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants publication-title: JAMA – volume: 160 start-page: 820 year: 2012 ident: hep31520-bib-0027-20241017 article-title: Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience publication-title: J Pediatr doi: 10.1016/j.jpeds.2011.10.038 – volume: 69 start-page: 626 year: 2018 ident: hep31520-bib-0029-20241017 article-title: Molecular profiling of subclinical inflammatory lesions in long‐term surviving adult liver transplant recipients publication-title: J Hepatol doi: 10.1016/j.jhep.2018.04.012 – volume: 18 start-page: 1680 year: 2018 ident: hep31520-bib-0010-20241017 article-title: Long‐term outcome of liver transplantation in childhood: a study of 20‐year survivors publication-title: Am J Transplant doi: 10.1111/ajt.14626 – volume: 14 start-page: 1582 year: 2008 ident: hep31520-bib-0001-20241017 article-title: Graft histology characteristics in long‐term survivors of pediatric liver transplantation publication-title: Liver Transpl doi: 10.1002/lt.21549 |
SSID | ssj0009428 |
Score | 2.608254 |
Snippet | Background and Aims
Tolerance is transplantation’s holy grail, as it denotes allograft health without immunosuppression and its toxicities. Our aim was to... Tolerance is transplantation's holy grail, as it denotes allograft health without immunosuppression and its toxicities. Our aim was to determine, among stable... Background and AimsTolerance is transplantation’s holy grail, as it denotes allograft health without immunosuppression and its toxicities. Our aim was to... BACKGROUND AND AIMSTolerance is transplantation's holy grail, as it denotes allograft health without immunosuppression and its toxicities. Our aim was to... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1985 |
SubjectTerms | Alanine Alanine transaminase Allografts Biopsy Child Child, Preschool Corticosteroids Female Fibrosis Graft rejection Graft Rejection - epidemiology Graft Rejection - etiology Hepatology Histology Humans Immunological tolerance Immunosuppression Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Infant Liver transplantation Liver Transplantation - adverse effects Liver Transplantation - methods Liver transplants Male Pediatrics Precision Medicine - methods Prospective Studies Safety Tacrolimus Withholding Treatment |
Title | Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.31520 https://www.ncbi.nlm.nih.gov/pubmed/32786149 https://www.proquest.com/docview/2519319622 https://search.proquest.com/docview/2434059672 |
Volume | 73 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hDlUvPNoCW2jloh56Ceza3jhpT1W7aIu6FSogOCBFdmyLFVV2xWaF4MofZ8Z5rGhVCXGLEjtOPB7PjP35G4CPyvLYeyFQ05yMJJqYKBW6i3qlU4X6ZHTIRTD6FQ9P5eF5_3wJvjRnYSp-iHbBjTQjzNek4NrM9hekoZcOA3a0PhSv94QiON_33wvqqFSGvKoYdVHDIm1Yhbp8v6352Bb942A-9leDwTlYhYvmUyucydXevDR7-d1fLI7P_Jc1WKkdUfa1GjnrsOSKV_BiVG-1v4b7AZFL6PyW6cKyY-1decsmnv2gAyWT2XxaI2gLdjYuL-21vsG3jQvW5v5gPwnywSr29D8oQIYu6nhK5y9nn9korGSwk4DaZUdNSHDnLFsgct7A6cHg5NswqjM2RDkx-UU8FrbLtbH9JE5NX2kygibW0hEPvlF5V3sllI6d11a4PFEaI1DZszbxNBWIDVguJoXbAmYSfE6wAKwh48QnOHvEvZ6XHu961-_AbiO7bFoRc2QVBTPPsDuz0J0d2GmkmtW6OcvorC5NPJx34EP7GLWKtkp04SZzLCOFpMRECstsVqOhbUVwlaBTk3bgU5Dp_5vPhoOjcPH26UW34SUn2EzAVO7Acnk9d-_Q7ynN-zDAHwC1Z_5k |
link.rule.ids | 314,780,784,1375,27924,27925,46294,46718 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fT9swED4hkNhetsHY1o0xb9rDXgKt7cYJ2ssERYW1CLEieJkiJ7ZFtSmtaCoEr_vHuXN-VIAmTXuLEjtOfD7fnf35O4DPyvDQOSFQ06wMJJqYIBa6jXqlY4X6lGqfi2B4HPbP5NFF92IJvtZnYUp-iGbBjTTDz9ek4LQgvbNgDb20GLGj-cGAfQXVvUOArv3TBXlULH1mVYy7qGkR17xCbb7TVL1vjR65mPc9Vm9yDp7Dz_pjS6TJr-15kW5ntw94HP_3b17As8oXZd_KwbMGSzZfh9Vhtdv-Ev70iF9CZzdM54b90M4WN2zi2CGdKZnM5tMKRJuz83Fxaa70Nb5tnLMm_QcbEOqDlQTqv1GGDL3U8ZSOYM522dAvZrCRB-6ykzoquLWGLUA5G3B20Bvt9YMqaUOQEZlfwENh2lynphuFcdpVmuxgGmppiQo_VVlbOyWUDq3TRtgsUhqDUNkxJnI0G4hXsJxPcvsGWBrhc0IGYA0ZRi7CCSTsdJx0eNfZbgs-1cJLpiU3R1KyMPMEuzPx3dmCzVqsSaWes4SO69Lcw3kLPjaPUbFot0TndjLHMlJIyk2ksMzrcjg0rQiuIvRr4hZ88UL9e_NJv3fiL97-e9EP8KQ_Gg6SweHx93fwlBOKxkMsN2G5uJrb9-gGFemWH-13ohEClA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9NQ5p4gY2vdR9gEA-8ZGtt107gCbFWHaxTBZvYA1LkxLZWMaXVmgptr_zj3Dkf1UBIiLcosePE5_uy734H8FpbrrwXAjnNyUiiiokSYbrIVybRyE-ZCbUIxqdqdC4_XvQv1uBdkwtT4UO0G27EGUFeE4PPrT9cgYZeOnTYUfugv35PKp4QcP7R5xV2VCJDYVV0u2hkkTSwQl1-2Ha9q4z-sDDvGqxB4wwfwrfmW6tAk-8HyzI7yG9_g3H8z5_ZhAe1JcreV0tnC9Zc8Qg2xvVZ-2P4OSB0CZPfMFNY9sV4V96wmWfHlFEyWyzndQhtwb5Oy0t7bX7g26YFa4t_sBOK-WAVfPoVUpChjTqdUwLm4i0bh60MdhbCdtmk8QlunWWrkJwncD4cnH0YRXXJhignKL-IK2G73GS2H6sk62tDWjBTRjoCws903jVeC22U88YKl8faoAsqe9bGnmSBeArrxaxw28CyGJ9TXAD2kCr2MYoP1et56fGud_0OvGpol84rZI60wmDmKU5nGqazA3sNVdOaORcpJeuS5OG8Ay_bx8hWdFZiCjdbYhspJFUm0tjmWbUa2lEE1zFaNUkH3gSa_n34dDSYhIudf2_6AjYmR8P05Pj00y7c5xRCE-Ir92C9vF66fbSByux5WOu_AJ8-AUM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+Safety+of+Immunosuppression+Withdrawal+in+Pediatric+Liver+Transplant+Recipients%3A+Moving+Toward+Personalized+Management&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Feng%2C+Sandy&rft.au=Bucuvalas%2C+John+C&rft.au=Mazariegos%2C+George+V&rft.au=Magee%2C+John+C&rft.date=2021-05-01&rft.eissn=1527-3350&rft.volume=73&rft.issue=5&rft.spage=1985&rft.epage=2004&rft_id=info:doi/10.1002%2Fhep.31520&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |